The controversy regarding the role of TNFĮ in cancer progression may be explained by our findings which demonstrate that while soluble TNFĮ (the form most studied) promotes cancer growth, the membrane-bound form of TNFĮ inhibits tumor growth by reducing tumor-associated myeloid cells.
INTRODUCTION
TNFĮ is a major inflammatory cytokine expressed within the tumor microenvironment.
TNFĮ is not normally detected in the serum of healthy individuals, but elevated levels have been detected in patients with prostate, pancreatic, renal cell, hematopoietic and metastatic breast cancers (1) (2) (3) (4) (5) (6) . The role of TNFĮ in cancer progression is conflicting. Multiple studies have demonstrated a pro-tumorogenic role of TNFĮ in vivo, in part by inhibiting necrosis of and by stimulating a proangiogenic myeloid phenotype (7, 8) . Despite the growing body of evidence showing that TNFĮ can function as a tumor promoter, there remain conflicting findings. Several case reports describe a temporal relationship between development of skin malignancies and lymphoma and the use of TNFĮ inhibitors (9, 10) . Moreover, the use of infliximab, which prevents binding of TNFĮ to its receptors, does not improve clinical outcome in renal cell carcinoma (11) . Collectively, these data demonstrate the complexity of TNFĮ in cancer pathogenesis.
The majority of studies to date focus on the 17-kDa soluble moiety of TNFĮ, which is released after proteolytic cleavage of the 26-kDa type II transmembrane isoform by TNFĮ-converting enzyme (TACE; ADAM-17) (12) . The role of membrane form of TNFĮ and its expression pattern in different tissue is poorly understood. Cardiac-restricted expression of membrane versus soluble TNFĮ isoform has been shown to have adverse effect in cardiac remodeling (13, 14) . Expression of sTNFĮ in cardiomyocytes can cause dilation of left ventricle in mice whereas the mTNFĮ results in a concentric hypertrophic cardiac phenotype. Increased mTNFĮ expression on T-cells is shown to modulate monocytes IL10 production (15) . In spite of these findings, the role of mTNFĮ in tumor biology is unknown (13) . Thus far it is not known whether tumors can express both isoforms. In addition there is little understanding of the difference in the mechanism of action of sTNFĮ versus mTNFĮ in regulating tumor behavior or impact on the tumor inflammatory stroma. The goal of the current study was to assess if the conflicting data regarding the association of TNFĮ with tumor progression was due to distinct effects of tumor expression of membrane vs. soluble isoforms. We found that whereas sTNFĮ expression promoted tumor growth, mTNFĮ-expressing tumors exhibited reduced growth and were largely devoid of myeloid cells. Our study demonstrated distinct TNFĮ isoform-dependent effects on myeloid cell survival.
Importantly, we showed for the first time that human non-small cell lung cancer (NSCLC) tissues exhibit differential expression of membrane versus soluble TNFĮ. Moreover, patients with lung tumors predicted by the molecular signature to have higher mTNFĮ had better survival when compared to patients with tumors with higher soluble form of TNFĮ expression. Together, these data demonstrate that opposing functions of membrane versus soluble TNFĮ significantly impact tumor progression for several cancer types, including NSCLC, one of the most commonly diagnosed cancer in the United States and one of the most difficult to treat (16) .
Strategies for molecularly targeted anti-TNFĮ agents must include screening patients for expression of each isoform and tailoring inhibitors to specifically target the soluble isoform. 
MATERIALS AND METHODS
Mice and cell lines. Wild-type C57Bl/6 (WT) mice were purchased from Jackson Laboratory.
Homozygous mutants for TNFR1 and R2 knockout (TNFR-DKO) on a C57Bl/6 background were a generous gift from Dr. D. Polk. Lewis Lung Carcinoma (LLC), B16F10 melanoma, and RAW 264.7 cells were purchased from American Type Culture Collection (ATCC) and maintained in DMEM supplemented with glucose (4.5 g/l) along with penicillin (10 U/L), streptomycin (10 ȝg/ml), plasmocin (25 ȝg/ml), amphotericin-B (2.5 ȝg/ml). H520, HCC95, SW900, H157, HCC15, and A549 were provided by Dr. P. P. Massion and were maintained in RPMI 1640 medium (Gibco). A549 cells were maintained in Ham's F-12K medium (Gibco). All cell lines were supplied with 10% (v/v) fetal bovine serum and incubated at 37°C in 5% CO 2 .
Constructs and retroviral transductions. Secretable TNFĮ was generated by replacing amino acids -76 to -1 containing the cytoplasmic signal-anchor for type II membrane protein and a short extracellular region with a sequence coding for the IL-2 signal peptide (IL2sp, amino acids -20 to -1) that directs the transport of TNFĮ to the outer cellular space and produces a solely secretable form of 17-kDa TNFĮ. This was done by amplifying mouse wild-type TNFĮ cDNA using forward primers flanked by BamH1-IL2sp. The amplified fragment was isolated and purified by gel electrophoresis. The restriction sites at each end allowed ligation of the IL2sp-TNFĮ fragment into the BamH1-EcoR1 site of LZRS-IRES-Neo retroviral vector, conferring neomycin resistance. The mTNFǻ1-9, K11E sequence encoding a mutant transmembrane TNFĮ molecule with a deletion at the cleavage site between presequnce and mature membrane TNFĮ (BCCM/LMBP plasmid collection, Ghent University) was also cloned into LZRS. This mutation prevents cleavage of the 26-kDa membrane TNFĮ into secretory TNFĮ isoform. An empty LZRS vector was used as a control vector.
(PBS, 2 mM EDTA, 0.5% BSA) and incubated for 5 min in RBC lysis buffer solution (155 mM NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA). Cells were washed twice in FACS buffer and incubated with anti-CD3 (Biolegend), -Ly6G (BD Pharminogen), -F480 (eBioscience) andCD11b+ (BD Pharminogen). After two washes, labeled cells were resuspended in vital dye 7-AAD (BD Pharminogen) and subjected to flow cytometry on LSRFortessa flow cytometer (Becton, Dickinson and Company, Franklin Lakes, NJ) and analyzed by using FlowJo software (TreeStar, Ashland, OR). were harvested and single-cell suspensions were made. CFSE labeled cells were detected using flow cytometry.
Caspase 3/7 activity. Freshly isolated CD11b+ (10 5 /96-well) were cocultured with fixed control, control+recTNFĮ (100 U/mL), and mTNFĮ B16F10 cells at CD11b+/tumor cells ratio of 1:10 for 5 hours. Apoptosis was quantified in the form of caspase-3/7 activation using the Apo-One fluorometric assay system from Promega Corporation (Madison, WI) according to the manufacturer's protocol.
Measurement of intracellular ROS.
The oxidant-sensing probe CM-H2DCFDA (Invitrogen) was used to detect intracellular reactive oxygen species (ROS). Freshly isolated CD11b+ cells were loaded with 10 ȝM CM-H2DCFDA, and cocultured with fixed B16F10 control, control+100 U/ml of recombinant TNFĮ, mTNFĮ or mTNFĮ+2 mM N-acetyl-cysteine (NAC) for 8 hours.
Fluorescence was determined using a luminescence spectrophotometer (Spectra max, (17) . The data set included gene-expression profiles for 442 lung adenocarcinomas with highquality gene-expression data, pathological data and clinical information. The association between gene expression and the survival was examined using the Cox proportional hazard model. Kaplan-Meier curves were generated to visualize the survival pattern by dichotomizing the gene-expression. The subgroup analysis of mTNFĮ and TACE was done by dividing the cohort into 4 groups of high TNFĮ with high/low TACE or low TNFĮ with high/low TACE. Logrank overall tests were performed for the 4 groups. All statistical analyses were performed using R (www.r-project.org).
Statistical analysis.
The statistical significance between experimental and control groups was determined by Student's t-test or ANOVA followed by Tukey's post-test using Prism software (Graphpad, San Diego, CA). A P-value of <0.05 was considered statistically significant.
RESULTS mTNFĮ isoform reduces tumor growth.
In this study we investigated the effects of different TNFĮ isoforms on malignant tumor phenotypes using murine Lewis Lung Carcinoma (LLC) sublines expressing either sTNFĮ (LZRS-IRES-IL2spTNFĮ) or mTNFĮ (LZRS-IRES-mTNFǻ1-9) by retroviral transduction ( To evaluate whether overexpressing various TNFĮ isoforms affected growth or survival of tumor cells, we assessed in vitro proliferation and viability using the BrdU incorporation and MTT assay, respectively. Both IL2spTNFĮ and mTNFĮ-expressing cells exhibited similar in vitro growth rates compared with control LLC lines (P>0.05; Fig. 1C ). IL2spTNFĮ and mTNFĮ LLC cell lines tested for viability also displayed similar levels of survival rate compared to control (P>0.05; Fig. 1D ). To gain additional evidence that the membrane isoform did not reduce survival or viability and that these observations were not cell specific, we transduced B16F10-melanoma cell lines with retroviral constructs, containing mTNFĮ or an empty construct as control cells. Similar to LLC lines, the proliferation rate (P>0.05) and viability (P>0.05) were not affected in mTNFĮ-expressing B16F10 cells compared to control cells ( Supplementary Fig. S1A and B). These findings are consistent with earlier studies in which we showed that overexpressing the wild-type TNFĮ in both LLC and B16F10 melanoma did not alter in vitro growth (8) . 
Expression of mTNFĮ does not affect tumor proliferation or vascularity in vivo.
To evaluated tumor vascular density and tumor cell proliferation rate, histological sections from control, IL2spTNFĮ and mTNFĮ LLC tumor were immunostained with platelet/endothelial cell adhesion molecule-1 (PECAM-1) antibody to evaluate microvessel density, and anti-Ki67 to assess tumor cell proliferation ( conditioned media (CM) from LLC and B16F10 melanoma cell lines expressing various forms of TNFĮ to promote migration (i.e. recruitment) of primary murine CD11b+ myeloid cells. CM from mTNFĮ did not inhibit migration of CD11b+ as compared to control-CM in both LLC and B16F10 melanoma line (Fig. 4A and Supplementary Fig. S6A ). An increase in CD11b+ myeloid cells migration was observed in CM derived from both IL2spTNFĮ-expressing LLC (~1.5-fold; Fig.   4B ) and B16F10 line (~4-fold; Supplementary Fig. S6B ). This may be attributed to the presence of TNFĮ itself, which is known to induce chemotactic response (19, 20) . These results suggested that the relative paucity of myeloid cells in mTNFĮ-expressing tumors was likely not due to reduced expression of key cytokines, necessary for myeloid extravasation and migration into the tumor. We further assessed the activation of apoptotic pathway in RAW 264.7 cells by determining the level of Bax/Bcl-2of and cleavage/activation of caspase-3 proteins in RAW 264.7. The data suggested that the Bax/Bcl-2 ratio (Fig. 5C ) and active-caspase-3 (Fig. 5D) proteins in RAW 264.7 cells treated with both soluble and membrane TNFĮ had no significant changes when compared to control. Together these findings are indicative of another death pathway independent of apoptosis.
NF-țB is a critical factor in the determination of cell death versus survival and proliferation (21, 22) . In cases of failed NF-țB activation, TNFĮ can induce either programmed cell death or necrosis through complex signal transduction cascades (23) . To evaluate whether soluble versus mTNFĮ isoforms induced distinct cellular responses via regulation of NF-țB, we tested NF-țB activity in RAW 264.7 cells co-cultured with FxB16 cont , FxB16 cont +rTNFĮ, or FxB16 mTNF . As shown in Figure 5E , the level of NF-țB p65 phosphorylation activity in RAW 264.7 cells stimulated with both FxB16 cont +rTNFĮ and FxB16 mTNF was similar to FxB16 cont , suggesting that mTNFĮ isoform did not affect the activity of NF-țB p65 compared to sTNFĮ.
mTNFĮ-induced cell death occurs through induction of ROS.
TNFĮ can induce cell death by induction of intracellular reactive oxygen spices (ROS) (24, 25) . To test the possibility that soluble versus membrane TNFĮ isoforms induced distinct cellular responses via regulation of intracellular ROS, we evaluated ROS levels in 
Relative expression pattern of TNFĮ/TACE correlates with survival probability in lung cancer patients.
In most studies, the role of TNFĮ in cancer has only been investigated in murine models or in modified cell lines and to our knowledge the expression level of mTNFĮ has not been evaluated in human tumors. To extend the relevance of our findings from the murine model to human cancer, we examined 62 tissue cores available in a single human non-small cell lung carcinoma (NSCLC) tissue array containing squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Using co-immunofluorescent staining analysis with anti-TNFĮ and carcinomaenriched membrane antigen (EMA) we evaluated the distribution of both degree (high-or low- were positive for both membrane and cytoplasmic TNFĮ. Twenty two (65%) showed low expression of TNFĮ with 18.3% cytoplasmic, 31.8% membrane and 50% with both membrane and cytoplasmic (Fig. 7A) . These data are the first evidence for the existence of mTNFĮ in human tumors and that its level varies significantly from patient to patient. Moreover, its level and localization varies significantly from patient to patient, which is likely an important consideration in predicted therapeutic response to anti-TNF agents based on our pre-clinical observations.
To provide further evidence that human tumors exhibit varying expression of TNFĮ isoforms, the expression of sTNFĮ was determined by ELISA of CM and the expression of mTNFĮ was evaluated by immunoblot analysis of cell membrane fraction. The analysis showed significant variation in the relative expression of membrane versus soluble TNFĮ among different human lung cancer-derived cell lines (Fig. 7B ).
Next we investigated the possible association of sTNFĮ ҏ versus mTNFĮ ratio with patient outcome (17) . It has been shown that there is a positive correlation between TACE surface expression and TNFĮ cleavage. Upregulation of TACE protein has also been shown to be associated with a decline in mTNFĮ level and increased soluble level and vice versa (27) .
Using publicly accessible NSCLC microarray database (n=442 patients), we divided the gene expression data into four groups. The first two groups featured low TNFĮ gene expression and low or high TACE. The third and fourth groups demonstrated high TNFĮ with either low or high TACE. Over all higher TACE level was significantly correlated to lower survival probability. Many soluble proteins such as TNFĮ are originally expressed as a membrane-bound form and then processed to a secretory form through proteolytic cleavage. Some of these proteins such as Fas ligand, a member of TNFĮ super family, have been described to have distinct biological effects on disease process as a membrane isoform when compared to the soluble isoform (32) . In this study we sought to better understand the role of different TNFĮ isoforms in the modulation of tumor progression and to determine if some of the reported opposing effects can be attributed to distinct effects of these isoforms.
We generated tumor cell lines expressing either uncleavable mTNFĮ or sTNFĮ. Multiple pathways have been shown to lead to ROS generation upon TNFR activation (24, 43) . this by immunofluorescence staining of tumor section for TNFĮ. The fact that mTNFĮ is present in tumor and at different levels and subcellular localization may provides important clues to divergent outcomes seen in TNFĮ positive tumor phenotype seen in different patients.
As it previously described, in order to generate sTNFĮ, the membrane associated TNFĮ is cleaved through proteolytic activity of TACE. Although it has been suggested that other proteinases are capable of TNFĮ cleavage it has been shown that TACE has the highest affinity for TNFĮ ectodomain shedding among the other known substrate (27) . Level of TACE present on the surface of the membrane has been inversely correlated with the level of membrane associated TNFĮ and inhibition of TACE by MMP inhibitors has demonstrated a transient increase in mTNFĮ surface expression (27, 46) . These studies suggest that the regulation of TACE activity and subsequent alteration of the sTNFĮ to mTNFĮ ratio could have a great impact on tumor growth. The association between higher TACE and higher TNFĮ gene expression in NSCLC and decreased survival further confirms the importance of different TNFĮ isoforms availability on tumor regulation.
Recently several Phase I/II clinical trials have been undertaken with TNFĮ antagonists in cancer patients (47) (48) (49) . In these clinical trials, TNFĮ antagonist treatment resulted in a period of disease stabilization in only 20% of the patients with advanced cancer. It is suggested that in order to take this forward, we need to identify those patients who are most likely to benefit from TNFĮ antagonist treatment. Perhaps determining the predominant form of TNFĮ expressed by tumor in these patients would be beneficial for a more effective treatment with TNFĮ inhibitors which can block both soluble and membrane isoforms.
In summary, we demonstrate that TNFĮ membrane versus soluble isoforms have opposing effects on cancer growth. Expression of both forms of TNFĮ in NSCLCs indicates that this finding is relevant to human malignancies and that isoform analysis should be applied to identify candidates for which anti-TNFĮ agents are likely to be beneficial versus detrimental. Analysis of the publicly available data from the Shedden cohort (17) was used to correlate TNFĮ/TACE expression pattern with survival probability (n=442, log rank P=0.035).
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